Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v1-EN
Language French English
Date Updated 2019-08-13 2019-08-13
Drug Identification Number 02243333 02243333
Common or Proper name Ferrlecit Ferrlecit
Ingredients IRON IRON
Strength(s) 12.5MG 12.5MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10 10
ATC code B03AC B03AC
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-09-30 2019-09-30
Actual start date
Estimated end date 2019-11-30 2019-11-30
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Company comments Delay in testing - Sanofi-aventis Canada Inc. would like to inform health care providers of an anticipated potential shortage for FERRLECIT, which may be caused by a delay in standard testing. It is possible that the situation is resolved by the beginning of September, in which case stock availability would not be affected. However due to the importance of this medication, we are communicating this situation as early as possible. The anticipated resolution date provided for this potential shortage is our best conservative estimate at this time. Allocation of current stock is in place to ensure availability of the product for as many patients as possible. Allocation is given based on historical purchase figures. Please note: The anticipated availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Delay in testing
Health Canada comments